We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sirolimus versus mycophenolate mofetil for triple immunosuppression in thyroid eye disease patients with recent‐onset intractable diplopia: A prospective comparative case series.
- Authors
Lai, Kenneth K. H.; Wang, Yue; Pang, Chi Pui; Chong, Kelvin K. L.
- Abstract
This article discusses a study comparing the effectiveness of sirolimus and mycophenolate mofetil (MMF) in treating thyroid eye disease (TED) patients with intractable diplopia. The study found that patients who received sirolimus had better improvement in diplopia compared to those who received MMF. The researchers also noted that sirolimus had antifibrotic effects on the orbital tissues in TED patients. No severe side effects were reported from either medication. The document describes the use of sirolimus as a treatment for thyroid eye disease (TED) patients with diplopia, highlighting its effectiveness in improving diplopia in patients who were refractory to conventional immunosuppressants. The authors suggest further exploration of sirolimus as a treatment option for TED patients and the need for future clinical trials to study its role as a monotherapy.
- Subjects
RAPAMYCIN; MYCOPHENOLIC acid; THYROID eye disease; DIPLOPIA; IMMUNOSUPPRESSION
- Publication
Clinical & Experimental Ophthalmology, 2023, Vol 51, Issue 8, p878
- ISSN
1442-6404
- Publication type
Article
- DOI
10.1111/ceo.14290